DA‐7503, a novel tau aggregation inhibitor, ameliorates tau pathology and reduces CSF tau in transgenic mouse models of Alzheimer’s disease and primary tauopathies
Min Jung Lee, Song‐hyen Choi, Jun‐Hwan Moon, Hyangsoo Lee, Eunjin Kim, Dae Young Lee, Sungsu Lim, Yun Kyung Kim, Ae Nim Pae · 2025
Read DA‐7503, a novel tau aggregation inhibitor, ameliorates tau pathology and reduces CSF tau in transgenic mouse models of Alzheimer’s disease and primary tauopathies by Min Jung Lee, Song‐hyen Choi, Jun‐Hwan Moon, Hyangsoo Lee, Eunjin Kim, Dae Young Lee, Sungsu Lim, Yun Kyung Kim, Ae Nim Pae (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11713001.txt.
Description
Min Jung Lee and eight colleagues test a new drug candidate, published in 2025, in mice bred to develop tau disease. Tau buildup in the brain marks Alzheimer disease and a set of related illnesses called tauopathies. Tau also leaks into spinal fluid, where its level may track disease activity. The drug, DA-7503, was built to stop tau from clumping.
The mice got the drug by mouth for one month. Treated mice did better on memory and recognition tests than untreated ones. Their brains showed less tau clumping and less of a harmful chemical change to tau. Spinal fluid tau also fell, and it fell more when drug levels ran higher. A second mouse type showed the same drop in harmful tau in the cortex. The authors argue the drug is a strong candidate and that spinal fluid tau could track its effect in future trials.
Catalog record
| CREATOR | Min Jung Lee, Song‐hyen Choi, Jun‐Hwan Moon, Hyangsoo Lee, Eunjin Kim, Dae Young Lee, Sungsu Lim, Yun Kyung Kim, Ae Nim Pae |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |